Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

Susan Fox; Montague Silverdale; Mark Kellett; Rhys Davies; Malcolm Steiger; Nicholas Fletcher; Alan Crossman; Jonathan Brotchie

doi:10.1002/mds.10693

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

Susan Fox, Montague Silverdale, Mark Kellett, Rhys Davies, Malcolm Steiger, Nicholas Fletcher, Alan Crossman, Jonathan Brotchie

The Walton Centre NHS Foundation Trust

Research output: Contribution to journal › Article › peer-review

Abstract

Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia.

Original language	English
Pages (from-to)	554-560
Number of pages	7
Journal	Movement disorders : official journal of the Movement Disorder Society
Volume	19
Issue number	5
DOIs	https://doi.org/10.1002/mds.10693
Publication status	Published - May 2004

Keywords

Antiparkinson Agents/adverse effects
Cross-Over Studies
Dose-Response Relationship, Drug
Double-Blind Method
Dyskinesia, Drug-Induced/drug therapy
Follow-Up Studies
Humans
Levodopa/adverse effects
Naloxone/administration & dosage
Narcotic Antagonists/administration & dosage
Parkinson Disease/drug therapy
Videotape Recording

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/mds.10693

Cite this

@article{c7655ab258bc4447bf78c2072ccb6ffa,

title = "Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease",

abstract = "Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia.",

keywords = "Antiparkinson Agents/adverse effects, Cross-Over Studies, Dose-Response Relationship, Drug, Double-Blind Method, Dyskinesia, Drug-Induced/drug therapy, Follow-Up Studies, Humans, Levodopa/adverse effects, Naloxone/administration & dosage, Narcotic Antagonists/administration & dosage, Parkinson Disease/drug therapy, Videotape Recording",

author = "Susan Fox and Montague Silverdale and Mark Kellett and Rhys Davies and Malcolm Steiger and Nicholas Fletcher and Alan Crossman and Jonathan Brotchie",

year = "2004",

month = may,

doi = "10.1002/mds.10693",

language = "English",

volume = "19",

pages = "554--560",

journal = "Movement disorders : official journal of the Movement Disorder Society",

issn = "0885-3185",

publisher = "John Wiley & Sons Ltd",

number = "5",

}

TY - JOUR

T1 - Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

AU - Fox, Susan

AU - Silverdale, Montague

AU - Kellett, Mark

AU - Davies, Rhys

AU - Steiger, Malcolm

AU - Fletcher, Nicholas

AU - Crossman, Alan

AU - Brotchie, Jonathan

PY - 2004/5

Y1 - 2004/5

N2 - Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia.

AB - Opioid peptide transmission is enhanced in the striatum of animal models and Parkinson's disease (PD) patients with levodopa-induced motor complications. Opioid receptor antagonists reduce levodopa-induced dyskinesia in primate models of PD; however, clinical trials to date have been inconclusive. A double-blind, placebo controlled, crossover design study in 14 patients with PD experiencing motor fluctuations was carried out, using the non-subtype-selective opioid receptor antagonist naloxone. Naloxone did not reduce levodopa-induced dyskinesia. The duration of action of levodopa was increased significantly by 17.5%. Non-subtype-selective opioid receptor antagonism may prove useful in the treatment of levodopa-related wearing-off in PD but not in dyskinesia.

KW - Antiparkinson Agents/adverse effects

KW - Cross-Over Studies

KW - Dose-Response Relationship, Drug

KW - Double-Blind Method

KW - Dyskinesia, Drug-Induced/drug therapy

KW - Follow-Up Studies

KW - Humans

KW - Levodopa/adverse effects

KW - Naloxone/administration & dosage

KW - Narcotic Antagonists/administration & dosage

KW - Parkinson Disease/drug therapy

KW - Videotape Recording

U2 - 10.1002/mds.10693

DO - 10.1002/mds.10693

M3 - Article

C2 - 15133820

SN - 0885-3185

VL - 19

SP - 554

EP - 560

JO - Movement disorders : official journal of the Movement Disorder Society

JF - Movement disorders : official journal of the Movement Disorder Society

IS - 5

ER -

Non-subtype-selective opioid receptor antagonism in treatment of levodopa-induced motor complications in Parkinson's disease

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this